| Literature DB >> 34411366 |
Filippo Ghidini1,2, Federica De Corti2, Francesco Fascetti Leon2, Enrico Vidal3, Alessandra Rancan2, Mattia Parolin4, Nicola Zadra5, Maurizia Grazzini5, Luca Maria Antoniello2, Alba Ganarin2, Sonia Maita2, Costanza Tognon5, Guendalina Mognato2, Marco Castagnetti1,6, Elisa Benetti4, Piergiorgio Gamba2, Patrizia Dall'Igna7.
Abstract
Extraperitoneal approach is sometimes recommended for kidney transplantation (KT) in children weighting <15 kg. We hypothesized that this approach might be as successful as in patients with normal weight. Data of all consecutive KTs performed between 2013 and 2019 were retrospectively reviewed. Early outcomes and surgical complications were compared between children weighing ≤15 kg (low-weight (LW) group) and those weighing >15 kg (Normal-weight (NW) group). All the 108 KTs were performed through an extraperitoneal approach. The LW group included 31 patients (mean age 3.5 ± 1.4 years), whose mean weight was 11.1 ± 2.0 kg. In the LW group,-a primary graft nonfunction (PNGF) occurred in one patient (3.2%), surgical complications occurred in nine (29%), with four venous thrombosis. In the NW group, PNGF occurred in one case (1.3%), delayed graft function (DGF) in eight (10%), surgical complications in 11 (14%) with only one case of venous thrombosis. In both groups, no need for patch during wound closure and no wound dehiscence were reported. The extraperitoneal approach can be effectively used in LW children. No differences were observed in the overall complication rate (P = 0.10), except for the occurrence of venous thrombosis (P = 0.02). This might be related to patients' characteristics of the LW group.Entities:
Keywords: complications; extraperitoneal approach; kidney transplantation; low-weight children
Mesh:
Year: 2021 PMID: 34411366 PMCID: PMC9292289 DOI: 10.1111/tri.14015
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.842
Perioperative characteristics of the population.
|
LW Group ( |
NW Group ( |
| |
|---|---|---|---|
| Male sex ( | 17 (55) | 43 (56) | 1.0 |
| Urological diseases as cause of ESKD ( | 16 (52) | 30 (39) | 0.23 |
| Kidney replacement therapy ( |
None 2 (6.5) Peritoneal 25 (81) Hemofiltration 2 (6.5) Both 2 (6.5) |
None 15 (19) Peritoneal 23 (30) Hemofiltration 21 (27) Both 18 (23) | <0.0001* |
| BWR (mean, SD) | 3.7 ± 1.7 | 1.9 ± 1.2 | 0.03* |
| Living donors ( | 8.0 (26) | 23 (30) | 0.82 |
| Nephrectomy of the native kidneys ( |
Monolateral 4 (13) Bilateral 5 (16) |
Monolateral 2 (2.6) Bilateral 3 (3.9) | 0.007* |
| Cold ischemia time‐nonliving donors (h; mean, SD) | 14 ± 4.9 | 11 ± 4.3 | 0.04 |
| Cold ischemia time‐living donors (h; mean, SD) | 1.4 ± 0.2 | 1.7 ± 0.3 | 0.37 |
| Warm ischemia time (min; mean, SD) | 58 ± 2.2 | 60 ± 11 | 0.94 |
| Anatomic variants ( | 9.0 (29) | 32 (42) | 0.28 |
| Operative time (min; mean, SD) | 272 ± 74 | 256 ± 47 | 0.57 |
| Heparin ( | 24 (77) | 44 (57) | 0.08 |
| Inotropic drugs ( | 22 (71) | 24 (31) | <0.001* |
| Vasodilating drugs ( | 7.0 (23) | 32 (42) | 0.08 |
*Significant P‐value ≤ 0.05.
Early outcomes of the KTs.
|
LW Group ( |
NW Group ( |
| |
|---|---|---|---|
| RI value (mean, SD) | 0.68 ± 0.17 | 0.66 ± 0.13 | 0.76 |
| DGF ( | 0 (0) | 8.0 (10) | 0.10 |
| PGNF ( | 1.0 (3.2) | 1.0 (1.3) | 0.49 |
| Serum Creatinine at discharge (µmol/l; mean, SD) | 32 ± 10 | 80 ± 50 | <0.001* |
| eGFR at discharge (ml/min/1.73 m2; mean, SD) | 92 ± 35 | 78 ± 29 | 0.009* |
| Length of hospital stay (days; mean, SD) | 19 ± 7.1 | 20 ± 8.6 | 0.83 |
*Significant for P‐value ≤ 0.05.
Surgical complications of KTs.
|
LW Group ( |
NW Group ( |
| |
|---|---|---|---|
| Overall surgical complications ( | 9 (29) | 11 (14) | 0.10 |
| Bleeding ( | 2 (6.5) | 5 (6.5) | 1.00 |
| Graft venous thrombosis ( | 4 (13) | 1 (1.3) | 0.02* |
| Urinary tract complications (n, %) | 2 (6.5) | 4 (5.2) | 1.00 |
| Other surgical complications ( | 1 (1.3) | 1 (3.2) | 0.49 |
*Significant for P‐value ≤ 0.05.
Figure 1Kaplan–Meier curve estimating one‐year allograft survival.
Results of one‐year allograft biopsies.
|
LW Group ( |
NW Group ( |
| |
|---|---|---|---|
|
Banff I Normal biopsy or nonspecific changes ( | 17 (65) | 47 (73) | 0.44 |
|
Banff II Antibody mediated changes ( | 7 (27) | 0 (0) | <0.0001* |
|
Banff III Suspicious (borderline) for acute T‐cell mediated rejection ( | 1 (3.8) | 9 (14) | 0.16 |
|
Banff IV T‐cell mediated rejection ( | 1 (3.8) | 8 (13) | 0.21 |
*Significant P‐value ≤ 0.05.